Back to News
Market Impact: 0.25
Tiziana Seeks FDA Orphan Drug Designation For Intranasal Foralumab
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Tiziana Life Sciences submitted a request to the FDA for Orphan Drug Designation for intranasal foralumab in Multiple System Atrophy. The filing could provide development and commercialization incentives if granted, but approval is not assured and no clinical efficacy or financial details were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
TLSA0.45
More News
- US judge approves settlement allowing Paramount to acquire Warner Bros
- Why is Nidec stock plunging today?
- California Gov. Gavin Newsom bans AI 'robo bosses' in landmark state law, reversing his earlier veto
- Google rolls out Gemini 4 Argon, its most advanced AI model
- OpenAI is sued over rogue AI Hugging Face cyberattack
- Trump's latest global tariffs face trade court challenge